New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:07 EDTAZN, GLYCGlycoMimetics appoints Pearson to board
GlycoMimetics (GLYC) announced the addition of Timothy Pearson to its board of directors. Pearson most recently held the position of CFO, executive vice president and treasurer at Catalyst Health Solutions. Pearson had previously served as CFO and executive vice president of medImmune, the global biologics business for AstraZeneca (AZN).
News For GLYC;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
11:13 EDTAZNBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 23, 2015
09:45 EDTAZNUBS to hold a field trip
Subscribe for More Information
09:06 EDTAZNInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
09:03 EDTAZNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:36 EDTAZNPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
07:55 EDTAZNAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
March 19, 2015
09:32 EDTGLYCGlycoMimetics to present preclinical data on GMI-1359 at AACR annual meeting
GlycoMimetics announced that new preclinical research on tumor growth and metastases and the potential value of its newest drug candidate, GMI-1359, will be presented at the American Association for Cancer Research Annual Meeting 2015 in Philadelphia. "Two posters will summarize research data on GMI-1359, a dual acting antagonist of both E-selectin and CXCR4, demonstrating its anti-tumor activity both alone and in combination with chemotherapy in preclinical models of pancreatic and prostate tumor growth. A third poster reports on preclinical studies where GMI-1271, an E-selectin specific antagonist, demonstrates complimentary yet differing roles of E-selectin and CXCR4 in breast cancer metastasis to bone," said the company. “Our initial data supports further evaluation of our E-selectin-CXCR4 antagonist and its potential role in addressing a variety of cancers, including those giving rise to bone metastases,” said John Magnani, Ph.D., GlycoMimetics VP and Chief Scientific Officer. “We... plan to continue our studies of this promising drug and a novel approach to addressing some of the most difficult to treat cancers.”
08:37 EDTAZNNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information
March 17, 2015
14:10 EDTAZNIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
06:11 EDTGLYCGlycoMimetics files $150M mixed securities shelf
Subscribe for More Information
March 16, 2015
16:37 EDTGLYCGlycoMimetics reports Q4 EPS (39c), consensus (22c)
Subscribe for More Information
07:30 EDTAZNAmerican College of Cardiology to hold an expo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use